Literature DB >> 78992

The natural history of metastatic renal cell carcinoma: a computer analysis.

J B Dekernion, K P Ramming, R B Smith.   

Abstract

Survival factors of 86 patients with metastatic renal cell carcinoma were studied by computer analysis. Cumulative survival was 53 per cent at 6 months, 43 per cent at 1 year, 26 per cent at 2 years and 13 per cent at 5 years. Survival was influenced favorably by confinement of metastases to the lungs, by the absence of local recurrence or persistence of tumor and by a longer interval free of disease after removal of the primary tumor. Medical therapy improved survival during the first year after diagnosis of metastases but no objective regression of tumor was observed. Excision of metastatic foci significantly improved survival for up to 5 years (p less than 0.05 and p less than 0.02) after which most patients died of recurrence. Palliative or adjunctive nephrectomy in patients with metastases was associated with a 6 per cent mortality rate but it increases survival over other patients with metastases at the time of diagnosis of renal carcinoma who did not undergo nephrectomy. This difference was owing to patient selection and survival of those who had adjunctive nephrectomy was no greater than that of the study population as a whole. However, based on the factors that were associated with improved survival palliative nephrectomy may be beneficial when a limited number of metastases treatable by excision or radiation therapy are present, when effective systemic therapy exists or when the primary tumor produces severe symptoms.

Entities:  

Mesh:

Year:  1978        PMID: 78992     DOI: 10.1016/s0022-5347(17)57082-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  61 in total

Review 1.  The role of resection for patients with renal carcinoma.

Authors:  R C Flanigan; P M Yonover
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 2.  Kidney cancer management in 2004: an update for the practicing general urologist.

Authors:  John S Lam; Oleg Shvarts; Arie S Belldegrun
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 3.092

Review 3.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

4.  Thyroid autoantibodies, telomerase activity, vascular endothelial growth factor, and bone scanning.

Authors:  A van Ophoven; B Patel; M K Rauch; A Belldegrun
Journal:  Rev Urol       Date:  1999

5.  Best of the 2000 AUA Annual Meeting: Highlights from the 95th American Urological Association Annual Meeting April 29-May 4, 2000, Atlanta.

Authors: 
Journal:  Rev Urol       Date:  2000

6.  Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells.

Authors:  A B Hansen; C B Andersen
Journal:  Urol Res       Date:  1994

7.  Metastases of renal cell carcinoma to the larynx and thyroid: Two case reports on metastasis developing years after nephrectomy.

Authors:  Lutfiye Demir; Cigdem Erten; Isil Somali; Alper Can; Ahmet Dirican; Vedat Bayoglu; Yuksel Kucukzeybek; Aysegul Aksoy Altinboga; Murat Ermete; Rukiye Mine Oztop; Mustafa Oktay Tarhan
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

Review 8.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

Review 9.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

10.  Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome.

Authors:  U Zimmermann; C Woenckhaus; S Pietschmann; H Junker; S Maile; K Schultz; C Protzel; J Giebel
Journal:  Virchows Arch       Date:  2004-08-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.